Answers are grounded in this paper and cite their sources.
Investigates agomiR-466 effects on oncogenic pathways in adrenocortical carcinoma, suggesting therapeutic potential.
Background Adrenocortical carcinoma (ACC) is an aggressive malignancy with limited therapeutic options, and microRNA (miRNA)-based strategies such as hsa-miR-466 have emerged as potential regulatory interventions. Purpose This study aimed to investigate the therapeutic potential of hsa-miR-466 in ACC using an integrative in silico framework. Methods An integrative pipeline that combined target prioritization, RNA–RNA interaction modeling, molecular docking, and ADMET/toxicity profiling was used. Among 394 upregulated transcripts, CHEK1, BUB1, and MELK were selected based on significant expression reversal (log₂FC < −3.4), unfavorable prognostic impact (HR > 2.9; p < .001), and energetically stable interactions (∆G: −13.2, −19.5, and −6.93 kcal/mol, respectively). Three-dimensional miRNA–mRNA duplexes were modeled and docked. Results The top docking clusters showed favorable HADDOCK scores (−19.9 for CHEK1, −27.2 for BUB1, −26.1 for MELK), low interface RMSDs (<1.5 Å), and multiple hydrogen bonds ( n = 4–5). Despite their high molecular weights (1,844–2,187 Da) and large polar surface areas (681–808 Ų), ADMET predictions indicated potential mutagenicity (AMES-positive) and hERG II inhibition signals, while no significant hepatotoxicity or hERG I inhibition was observed; however, the results should be interpreted with caution due to the limited applicability of small-molecule-based models to oligonucleotide systems. In addition, poor intestinal absorption, CNS impermeability, and efflux liability (P-gp substrates) were consistently observed. Off-target analysis via SEA identified 41 shared unintended protein targets (MaxTC > 0.5), including RNASE1 and purinergic receptors (P2RY2, P2RX4). Conclusion This study provides a proof-of-concept for AgomiR-466-guided targeting of mitotic kinases in ACC, while highlighting the limitations of current prediction models for oligonucleotide-based agents.
No takes yet. Share an insight, caveat, or question.
Javad Omidi (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: